Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : CardioDynamics (CDIC) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (125)	9/1/2001 9:32:13 PM
From: tom r. phillips	Respond to of 201

got a positive mention in Worden bros. TC 2000 charting service. that's the reason for the volume bump. tom

To: Arthur Radley who wrote (125)	10/12/2001 3:08:41 PM
From: tuck	Read Replies (1) \| Respond to of 201

TD, I sold on the spike, but may get back in soon. I don't think they'll get the penetration in the hypertension market that I'd expect them to get in the congestive heart failure market, but even a little success could provide substantial upside. Unless the incremental revenues don't outweigh the increased sales costs. Anyhow, the market looks wobbly and dubious of this PR this week. Consulting my charts for possible entry point . . . >>SAN DIEGO, Oct 9, 2001 /PRNewswire via COMTEX/ -- CardioDynamics International Corporation (Nasdaq: CDIC chart, msgs), the innovator and market leader of Impedance Cardiography (ICG) technology and manufacturer of BioZ(R) noninvasive digital cardiac function monitoring systems, today announced it is intensifying its focus on hypertension (high blood pressure), which has become an international health priority. A cover story published in the August 2001 Cardiovascular Disease Management, reports that the Company's BioZ(R) ICG is an effective, efficient, and less costly method of improving patient outcomes in the treatment of multi-drug resistant hypertension. The article affirms that ICG-guided therapy in hypertensive patients can avoid months of trial and error with multiple drug combinations and facilitates a more accurate drug selection and dose titration. This article follows a recent study conducted by the Mayo Clinic demonstrating a 65% improvement in effectively treating hypertensive patients with ICG, as compared to traditional management by high blood pressure specialist physicians. John E. Strobeck, M.D., Ph.D., Director of the Heart-Lung Associates of America, stated, "In our clinic, the use of monitoring with ICG has become a standard of care. For over three years, we have used this vital data to assist our physicians and nurses to fine-tune the pharmacologic and fluid management of hypertensive patients and those with heart failure. This new 'informed' approach to treatment is key in improving outcomes for the millions affected by high blood pressure, heart failure, and other cardiovascular diseases." "Up until now, CardioDynamics has focused its U.S. direct sales resources on a subset of the 27,000 cardiologists who are primarily treating heart failure patients," stated Michael K. Perry, CardioDynamics' Chief Executive Officer. "The Company is now broadening its reach to include the 157,000 internists, 93,000 family practitioners, and the main stream population of cardiologists who are responsible for the treatment of high blood pressure. The U.S. hypertension patient population is ten times more than the five million heart failure patients." An editorial entitled "Control of Hypertension -- An Important National Priority" published in the August 16, 2001 issue of The New England Journal of Medicine, stated, "More than one-fourth of the estimated 42 million people with hypertension in the United States remain unaware that they have the disorder, and approximately three-fourths of those with known hypertension have blood pressure that exceeds recommended levels. The problem is even greater in the rest of the world, where more than 800 million people, or more than 20 percent of the adult population, are considered to have hypertension and where rates of control are even worse than in this country." The editors further stated, "physicians' knowledge and attitudes about hypertension and the importance of achieving targeted blood-pressure levels are critical." The Company's BioZ ICG technology can play a significant role in providing objective knowledge and fighting the war against hypertension. Prior to the advent of ICG technology, physicians were limited to basic clinical examination, which included blood pressure, examining neck veins, and relying on subjective patient data and had to base drug treatments on trial and error. ICG technology now provides clinicians with 12 parameters of 'objective' data to enhance their understanding of the underlying causes of hypertension, select appropriate drugs, and improve the time it takes to control the patient's blood pressure. In a recent study funded by the U.S. Agency for Healthcare Research and Quality, the Agency reported there was a need for regular updating of medical guidelines at least every three years. The Company is planning initiatives to have its ICG technology included in several medical guidelines, including the treatment of hypertension and congestive heart failure.<< Cheers, Tuck